{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T22:38:49Z","timestamp":1788475129189,"version":"build-2803163510"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,7,4]],"date-time":"2022-07-04T00:00:00Z","timestamp":1656892800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Transplant-associated thrombotic microangiopathy (TA-TMA) is a serious complication of bone marrow transplantation (BMT). Recently, abnormalities in the complement system have been identified in the pathogenesis of TA-TMA, and there are series of reports stating that anti-C5 monoclonal antibody (eculizumab) is effective in patients with high levels of the membrane attack complex (C5b-9).<\/jats:p><\/jats:sec><jats:sec><jats:title>Case Presentation<\/jats:title><jats:p>A 12-year-old boy underwent autologous BMT after receiving high-dose chemotherapy for malignant lymphoma. The patient was engrafted on day 19 after transplantation; however, hemolytic anemia and non-immune thrombocytopenia persisted, and haptoglobin decreased on day 46. Moreover, on day 83, the patient developed pulmonary hemorrhage, hypertension, severe proteinuria, hematuria, and acute kidney injury (AKI). Pulmonary bleeding stopped with daily platelet transfusion and hemostatic agents, but reappeared on day 100. Based on the presence of destruction of red blood cells, elevated lactate dehydrogenase levels, negative direct and indirect Coombs tests, normal ADAMTS13 levels, hemolytic anemia, non-immune thrombocytopenia, and AKI, the patient was diagnosed with systemic TA-TMA and we initiated plasma exchange (PE) and continuous hemodialysis for AKI. High C5b-9 levels were identified at the start of the series of PE, therefore we decided to administer eculizumab. After three courses of eculizumab, no pulmonary hemorrhage was observed, and anemia, thrombocytopenia, renal dysfunction, hematuria, and proteinuria all tended to improve. Three years after transplantation, the patient is alive and does not require eculizumab.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>Eculizumab is a humanized monoclonal antibody that binds complement protein C5, preventing cleavage C5 and the formation of C5b-9. In this case, TA-TMA could not be controlled with PE alone. We therefore decided to use eculizumab relatively early based on the high C5b-9 level and could resolve the momentum of TA-TMA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In previous reports, TA-TMA typically occurred in early post-allogeneic BMT of patients with lymphoma or in post-autologous BMT of patients with neuroblastoma and was treated with eculizumab. We here reported that eculizumab could be successful treatment for TA-TMA in post-autologous BMT of patient with lymphoma.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fped.2022.908183","type":"journal-article","created":{"date-parts":[[2022,7,4]],"date-time":"2022-07-04T06:20:34Z","timestamp":1656915634000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Case Report: Successful Treatment With Anti-C5 Monoclonal Antibody in a Japanese Adolescent Who Developed Thrombotic Microangiopathy After Autologous Bone Marrow Transplantation for Malignant Lymphoma"],"prefix":"10.3389","volume":"10","author":[{"given":"Shoichi","family":"Shimizu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamaki","family":"Morohashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Kanezawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Yagasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shori","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiro","family":"Morioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,7,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.blre.2014.11.001","article-title":"A new paradigm: Diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injury","volume":"29","author":"Jodele","year":"2015","journal-title":"Blood Rev."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1182\/blood-2011-02-321315","article-title":"Small vessels, big trouble in the kidneys and beyond: hematopoietic stem cell transplantation-associated thrombotic microangiopathy","volume":"118","author":"Laskin","year":"2011","journal-title":"Blood."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1046\/j.1365-2141.2002.03721.x","article-title":"Thrombotic thrombocytopenic purpura after allogeneic stem cell transplantation: a survey of the European Group for Blood and Marrow Transplantation (EBMT)","volume":"118","author":"Ruutu","year":"2002","journal-title":"Br J Haematol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/sj.bmt.1705758","article-title":"Diagnosis and treatment of transplantation-associated thrombotic microangiopathy: real progress or are we still waiting?","volume":"40","author":"Batts","year":"2007","journal-title":"Bone Marrow Transplant."},{"key":"B5","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.blre.2012.05.001","article-title":"Thrombotic complications associated with stem cell transplantation","volume":"26","author":"Nadir","year":"2012","journal-title":"Blood Rev."},{"key":"B6","doi-asserted-by":"publisher","first-page":"133","DOI":"10.3389\/fped.2019.00133","article-title":"Transplant-associated thrombotic microangiopathy in pediatric hematopoietic cell transplant recipients: a practical approach to diagnosis and management","volume":"7","author":"Dvorak","year":"2019","journal-title":"Front Pediatr."},{"key":"B7","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.semnephrol.2010.09.010","article-title":"Chronic kidney disease after hematopoietic stem cell transplantation","volume":"30","author":"Cohen","year":"2010","journal-title":"Semin Nephrol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"761726","DOI":"10.3389\/fped.2021.761726","article-title":"Use of eculizumab in pediatric patients with transplant associated thrombotic microangiopathy","volume":"9","author":"Gomez-Ganda","year":"2021","journal-title":"Front Pediatr."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1182\/blood.2019004218","article-title":"Complement blockade for TA-TMA: lessons learned from a large pediatric cohort treated with eculizumab","volume":"135","author":"Jodele","year":"2020","journal-title":"Blood."},{"key":"B10","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1177\/1076029615599439","article-title":"Eculizumab in transplant-associated thrombotic microangiopathy","volume":"23","author":"Dhakal","year":"2017","journal-title":"Clin Appl Thromb Hemost."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1097\/TP.0000000000000601","article-title":"Use of eculizumab in patients with allogeneic stem cell transplant-associated thrombotic microangiopathy: a study from the SFGM-TC","volume":"99","author":"de Fontbrune","year":"2015","journal-title":"Transplantation."},{"key":"B12","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1111\/ejh.13127","article-title":"Eculizumab for transplant-associated thrombotic microangiopathy in adult allogeneic stem cell transplant recipients","volume":"101","author":"Rudoni","year":"2018","journal-title":"Eur J Haematol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"e13381","DOI":"10.1111\/petr.13381","article-title":"Severe, persistent neurotoxicity after transplant-associated thrombotic microangiopathy in a pediatric patient despite treatment with eculizumab","volume":"23","author":"Schoettler","year":"2019","journal-title":"Pediatr Transplant."},{"key":"B14","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.bbmt.2015.10.002","article-title":"Variable eculizumab clearance requires pharmacodynamic monitoring to optimize therapy for thrombotic microangiopathy after hematopoietic stem cell transplantation","volume":"22","author":"Jodele","year":"2016","journal-title":"Biol Blood Marrow Transplant."},{"key":"B15","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.bbmt.2006.11.020","article-title":"Transplant-associated microangiopathy in patients receiving tacrolimus following allogeneic stem cell transplantation: risk factors and response to treatment","volume":"13","author":"Oran","year":"2007","journal-title":"Biol Blood Marrow Transplant."},{"key":"B16","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.bbmt.2018.08.016","article-title":"Therapeutic plasma exchange does not improve renal function in hematopoietic stem cell transplantation-associated thrombotic microangiopathy: an institutional experience","volume":"25","author":"Sartain","year":"2019","journal-title":"Biol Blood Marrow Transplant."},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-022-01644-3","article-title":"Diffuse alveolar hemorrhage: An underreported complication of transplant associated thrombotic microangiopathy","author":"Agarwal","year":"2022","journal-title":"Bone Marrow Transplant."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1038\/nbt1344","article-title":"Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria","volume":"25","author":"Rother","year":"2007","journal-title":"Nat Biotechnol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1038\/bmt.2014.97","article-title":"Recovery from life-threatening transplantation-associated thrombotic microangiopathy using eculizumab in a patient with very severe aplastic anemia","volume":"49","author":"Okano","year":"2014","journal-title":"Bone Marrow Transplant."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1038\/s41409-018-0159-8","article-title":"High-dose Carboplatin\/Etoposide\/Melphalan increases risk of thrombotic microangiopathy and organ injury after autologous stem cell transplantation in patients with neuroblastoma","volume":"53","author":"Jodele","year":"2018","journal-title":"Bone Marrow Transplant."}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2022.908183\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,4]],"date-time":"2022-07-04T06:20:37Z","timestamp":1656915637000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2022.908183\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,4]]},"references-count":20,"alternative-id":["10.3389\/fped.2022.908183"],"URL":"https:\/\/doi.org\/10.3389\/fped.2022.908183","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,4]]},"article-number":"908183"}}